Yourway
6681 Snowdrift Road
Allentown, PA 18106
United States
Office:
Yourway
6681 Snowdrift Road
Allentown, PA 18106
United States
The U.S. Food and Drug Administration announced that it has granted the Orphan Drug Designation to APR Applied Pharma Research's investigational drug APR-TD011 for the treatment of epidermolysis bullosa, a group of debilitative, genetic connective tissue disorders. The designation will provide a range of benefits, including tax credits, FDA assistance in trial design, and seven years of market exclusivity upon approval. Yourway believes that developing treatments and conducting trials for patients with rare diseases is of critical importance.
Back to IndexJoin our newsletter mailing list to never miss an update!
Precision in Pharma Supply Chain Summit Boston
November 16-17, 2026
Boston, MA
SCOPE Supply Chain & Logistics Leadership Summit
March 1-4, 2027
Orlando, FL